Amy Blyskal's Colleagues at Prelude Therapeutics
Askold Sandursky
Executive Director, Head of Information Technologies at Prelude Therapeutics Incorporated
Amy Blyskal's Contact Details
(302) 467-1280
Wilmington,Delaware,United States
Prelude Therapeutics
Amy Blyskal's Company Details
Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. The Company’s diverse pipeline is comprised of highly differentiated, potentially best-in-class proprietary small molecule compounds aimed at addressing clinically validated pathways forcancers with selectable underserved patients. Prelude’s pipeline includes three candidates currently in clinical development: PRT3789 an IV administered, potent and highly selective SMARCA2 degrader, PRT2527, a potent and highly selective CDK9 inhibitor, PRT3645 a next generation CDK4/6 inhibitor, and a preclinical oral candidate targeting SMARCA2.